Case report: Multiple myeloma in renal transplant patient (2010)

Status:

Ready to upload

Record number:

2046

Adverse Occurrence type:

Multiple myeloma/plasmacytoma leukemia

MPHO Type:

Kidney

Estimated frequency:

Most recent risk assessment for leukemia, lymphoma and plasmacytoma (Council of Europe, 2022): Leukaemia, lymphoma and plasmacytoma diagnosed during donor procurement: These cancers are classified as an unacceptable risk for organ donation. Leukaemia, lymphoma and plasmacytoma in the donor history: Active (acute or chronic) leukaemia, lymphoma and plasmacytoma are an unacceptable risk for organ donation. Treated acute leukaemia and lymphoma after a definite disease-free interval of 10 years may be considered for organ donation with an assumed high risk for transmission.

Time to detection:

N/A

Alerting signals, symptoms, evidence of occurrence:

Backache, bone pain and allograft dysfunction. Bone survey showed extensive lytic lesions and bone marrow biopsy showed 30% plasma cells with lambda light chain expression.

Demonstration of imputability or root cause:

None

Imputability grade:

1 Possible

Groups audience:

Keywords:

PTLD (post-transplant lymphoproliferative disorder)

paid donor

References:

Cost of paid transplantation abroad: possible donor-origin early multiple myeloma in a renal transplant recipient treated using bortezomib

Suggest new keywords:

Malignancy

Case report

Kidney transplant

Multiple myeloma

Reference attachment:

Solak-2010-Cost of paid transplantation abroad.pdf

Suggest references:

Solak Y, Atalay H, Anil M, Aydogdu I, Tonbul HZ. Cost of paid transplantation abroad: possible donor-origin early multiple myeloma in a renal transplant recipient treated using bortezomib. Transplantation Proceedings. 2010;42(7):2813-5.

Note:

Carl-Ludwig: agree to Michael; case report with no data about onset, no attempted to confirm origin of myeloma. I can write a E-Mail to the author and ask for those missing data. ([email protected]).

Expert comments for publication:

The case report focuses on the fact that this was a paid transplant abroad, with no donor information. The myeloma occurred "a short time" after transplantation. However, nowhere in the report is it stated what this time interval is. Additionally, no studies were done to determine donor versus recipient origin of the tumor. Therefore, although it is possible that this was donor related, the evidence is circumstantial only and the possibility of a myeloma form of PTLD cannot be excluded. The patient did respond to bortezomib therapy but the allograft failed and he became dialysis dependent.